Vascular Biogenics Stock Price

-0.04 (-2.99%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Vascular Biogenics Ltd VBLT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Previous Close Last Traded
-0.04 -2.99% 1.30 1.29 1.37 1.31 1.34 19:53:23
Bid Price Ask Price Spread Spread % News
1.29 1.35 0.06 4.44% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
551 171,541 $ 1.32 $ 226,805 253,548 0.90 - 2.5099
Last Trade Time Type Quantity Stock Price Currency
19:56:21 20 $ 1.29 USD

Vascular Biogenics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 62.27M 47.90M 37.32M $ 562.00k $ - -0.55 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Vascular Biogenics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VBLT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.281.371.251.30232,4680.021.56%
1 Month1.251.451.201.29190,2430.054.0%
3 Months1.221.621.071.23585,3080.086.56%
6 Months1.422.50990.901.26370,613-0.12-8.45%
1 Year1.202.50990.901.27213,0170.108.33%
3 Years4.059.050.602.86202,216-2.75-67.9%
5 Years5.8412.250.604.33230,383-4.54-77.74%

Vascular Biogenics Description

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.